Literature DB >> 5335457

Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland.

O Horwitz, P G Payne, E Wilbek.   

Abstract

As knowledge of the epidemiology of tuberculosis in Greenland has increased, it has become evident that the majority of cases develop long after the primary infection and that it would therefore be valuable from the public health point of view if the disease rate among naturally infected persons could be reduced. To examine the possibility of achieving this, a double-blind drug trial with isoniazid and a placebo was conducted among some 70% of the adult population of western Greenland. The results show that throughout the six years of the study the incidence of tuberculosis was lower in the group treated with isoniazid and that this reduction occurred whether the initial X-rays pictures were normal or showed suspicious or healed lesions.It is concluded that chemoprophylaxis programmes should probably be administered only to selected groups of the population. The delimitation of such groups is discussed on the basis of their tuberculosis risk and of the expected yield in terms of reduction in tuberculosis prevalence.

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 5335457      PMCID: PMC2476023     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  10 in total

1.  A CONTROLLED TRIAL OF ISONIAZID PROPHYLAXIS IN MENTAL INSTITUTIONS.

Authors:  S H FEREBEE; F W MOUNT; F J MURRAY; V T LIVESAY
Journal:  Am Rev Respir Dis       Date:  1963-08

2.  Isoniazid prophylaxis in an undeveloped area.

Authors:  G W COMSTOCK
Journal:  Am Rev Respir Dis       Date:  1962-12

3.  Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts.

Authors:  S H FEREBEE; F W MOUNT
Journal:  Am Rev Respir Dis       Date:  1962-04

4.  Mass chemoprophylaxis of tuberculosis. The acceptability and untoward side effects of isoniazid in a control study in Greenland.

Authors:  E GROTH-PETERSEN; U GAD; F OSTERGAARD
Journal:  Am Rev Respir Dis       Date:  1960-05

5.  [Tuberculosis morbidity in Greenland].

Authors:  K S STEIN; E GROTH-PETERSEN
Journal:  Ugeskr Laeger       Date:  1957-04-04

6.  Chemoprophylaxis of tuberculosis.

Authors:  E GROTH-PETERSEN
Journal:  Acta Tuberc Scand       Date:  1957

7.  Studies on prevention of experimental tuberculosis with isoniazid. II. Effects of different dosage regimens.

Authors:  S H FEREBEE; L HOPWOOD; C E PALMER
Journal:  Am Rev Tuberc       Date:  1956-12

8.  Tuberculin survey in Greenland.

Authors:  M FOG-POULSEN
Journal:  Acta Tuberc Scand       Date:  1956

9.  Preventive effects of isoniazid in the treatment of primary tuberculosis in children.

Authors:  F W MOUNT; S H FEREBEE
Journal:  N Engl J Med       Date:  1961-10-12       Impact factor: 91.245

10.  The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis.

Authors:  F W MOUNT; S H FEREBEE
Journal:  Am Rev Respir Dis       Date:  1962-06
  10 in total
  10 in total

1.  Chapter 4. Public health benefits.

Authors: 
Journal:  Bull World Health Organ       Date:  1973       Impact factor: 9.408

2.  A program for tuberculosis control in the schools.

Authors:  G D Hanzel
Journal:  Am J Public Health Nations Health       Date:  1970-07

3.  Epidemiological basis of tuberculosis eradication. 11. Mortality among tuberculosis cases and the general population of Greenland.

Authors:  E Iversen
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

Review 4.  Isoniazid preventive therapy and risk for resistant tuberculosis.

Authors:  Maria Elvira Balcells; Sara L Thomas; Peter Godfrey-Faussett; Alison D Grant
Journal:  Emerg Infect Dis       Date:  2006-05       Impact factor: 6.883

5.  Using a single tablet daily to treat latent tuberculosis infection in Brazil: bioequivalence of two different isoniazid formulations (300 mg and 100 mg) demonstrated by a sensitive and rapid high-performance liquid chromatography-tandem mass spectrometry method in a randomised, crossover study.

Authors:  André Daher; Luciana Pitta; Tereza Santos; Draurio Barreira; Douglas Pinto
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-06-02       Impact factor: 2.743

6.  Is IPT more effective in high-burden settings? Modelling the effect of tuberculosis incidence on IPT impact.

Authors:  R Ragonnet; J M Trauer; E S McBryde; R M G J Houben; J T Denholm; A Handel; T Sumner
Journal:  Int J Tuberc Lung Dis       Date:  2017-01-01       Impact factor: 2.373

7.  Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020.

Authors:  Timothy R Sterling; Gibril Njie; Dominik Zenner; David L Cohn; Randall Reves; Amina Ahmed; Dick Menzies; C Robert Horsburgh; Charles M Crane; Marcos Burgos; Philip LoBue; Carla A Winston; Robert Belknap
Journal:  MMWR Recomm Rep       Date:  2020-02-14

Review 8.  What We Know About Tuberculosis Transmission: An Overview.

Authors:  Gavin Churchyard; Peter Kim; N Sarita Shah; Roxana Rustomjee; Neel Gandhi; Barun Mathema; David Dowdy; Anne Kasmar; Vicky Cardenas
Journal:  J Infect Dis       Date:  2017-11-03       Impact factor: 7.759

Review 9.  Designing and Evaluating Interventions to Halt the Transmission of Tuberculosis.

Authors:  David W Dowdy; Alison D Grant; Keertan Dheda; Edward Nardell; Katherine Fielding; David A J Moore
Journal:  J Infect Dis       Date:  2017-11-03       Impact factor: 5.226

10.  Estimating the long-term effects of mass screening for latent and active tuberculosis in the Marshall Islands.

Authors:  Romain Ragonnet; Bridget M Williams; Angela Largen; Joaquin Nasa; Tom Jack; Mailynn K Langinlur; Eunyoung Ko; Kalpeshsinh Rahevar; Tauhid Islam; Justin T Denholm; Ben J Marais; Guy B Marks; Emma S McBryde; James M Trauer
Journal:  Int J Epidemiol       Date:  2022-10-13       Impact factor: 9.685

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.